Press Releases

Sign up for Email Alerts Press Release RSS

11/12/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
11/11/2019
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma
Term:Corporate/Financial News
Language:English
11/07/2019
Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting1
Term:R&D News
Language:English
11/07/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
11/05/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
11/01/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English
10/31/2019
Bristol-Myers Squibb Reports Third Quarter Financial Results
Term:Corporate/Financial News
Language:English
10/30/2019
Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference
Term:Corporate/Financial News
Language:English
10/30/2019
Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT
Term:Corporate/Financial News
Language:English
10/30/2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm